TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ribomic, Inc. ( (JP:4591) ) has shared an update.
Ribomic Inc. reported its non-consolidated financial results for the three months ended June 30, 2025, showing no operating revenues and a net loss of 227 million yen, consistent with the previous year’s performance. The company’s financial position remains stable with a high equity ratio, but it continues to forecast a full-year loss, indicating ongoing financial challenges.
More about Ribomic, Inc.
Ribomic Inc. is a company listed on the Tokyo Stock Exchange, operating in the biotechnology sector. The company focuses on developing innovative therapeutic solutions, although specific products or services are not detailed in the release.
Average Trading Volume: 2,173,257
Technical Sentiment Signal: Buy
Current Market Cap: Yen5.31B
For an in-depth examination of 4591 stock, go to TipRanks’ Overview page.